http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 14 Jun 2026 08:05:49 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Lilly%27s+Jaypirca+reduces+disease+progression+risk+by+45%25+in+CLL+study/26642892.html <p>Eli Lilly and Company (NYSE: LLY) announced that its Phase 3 BRUIN CLL-322 clinical trial met its primary endpoint, showing that Jaypirca (pirtobrutinib) combined with venetoclax and rituximab reduced the risk of disease progression or death by 45% compared to venetoclax and rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).</p><p>The study enrolled 639 patients, with 79.8% having prior covalent BTK inhibitor exposure. Participants were randomized to receive either pirtobrutinib plus venetoclax and rituximab (321 patients) or venetoclax and rituximab alone (318 patients). At a median follow-up of 27.3 months, the combination therapy http://www.streetinsider.com/Corporate+News/Lilly%27s+Jaypirca+reduces+disease+progression+risk+by+45%25+in+CLL+study/26642892.html Sun, 14 Jun 2026 08:05:49 -0400 LLY http://www.streetinsider.com/FDA/Lilly%27s+Jaypirca+reduces+disease+progression+risk+by+45%25+in+CLL+study/26642892.html <p>Eli Lilly and Company (NYSE: LLY) announced that its Phase 3 BRUIN CLL-322 clinical trial met its primary endpoint, showing that Jaypirca (pirtobrutinib) combined with venetoclax and rituximab reduced the risk of disease progression or death by 45% compared to venetoclax and rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).</p><p>The study enrolled 639 patients, with 79.8% having prior covalent BTK inhibitor exposure. Participants were randomized to receive either pirtobrutinib plus venetoclax and rituximab (321 patients) or venetoclax and rituximab alone (318 patients). At a median follow-up of 27.3 months, the combination therapy http://www.streetinsider.com/FDA/Lilly%27s+Jaypirca+reduces+disease+progression+risk+by+45%25+in+CLL+study/26642892.html Sun, 14 Jun 2026 08:05:49 -0400 LLY http://www.streetinsider.com/Hot+Corp.+News/Lilly%27s+Jaypirca+reduces+disease+progression+risk+by+45%25+in+CLL+study/26642892.html <p>Eli Lilly and Company (NYSE: LLY) announced that its Phase 3 BRUIN CLL-322 clinical trial met its primary endpoint, showing that Jaypirca (pirtobrutinib) combined with venetoclax and rituximab reduced the risk of disease progression or death by 45% compared to venetoclax and rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).</p><p>The study enrolled 639 patients, with 79.8% having prior covalent BTK inhibitor exposure. Participants were randomized to receive either pirtobrutinib plus venetoclax and rituximab (321 patients) or venetoclax and rituximab alone (318 patients). At a median follow-up of 27.3 months, the combination therapy http://www.streetinsider.com/Hot+Corp.+News/Lilly%27s+Jaypirca+reduces+disease+progression+risk+by+45%25+in+CLL+study/26642892.html Sun, 14 Jun 2026 08:05:49 -0400 LLY http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/Press+Releases/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html <div class="xn-content"> <p class="prntac"><i>BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with </i><i>the majority of</i><i> patients previously treated with a covalent BTK inhibitor, reflects current practice patterns</i></p><p class="prntac"><i>These</i> <i>data</i> <i>will be highlighted in a late-breaking oral presentation</i> <i>at the 2026 <span>European Hematology Association</span> (EHA) Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 14, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and http://www.streetinsider.com/PRNewswire/Lilly%27s+Jaypirca+%28pirtobrutinib%29+significantly+reduced+the+risk+of+disease+progression+or+death+by+45%25+when+added+to+a+venetoclax+time-limited+regimen+in+people+with+previously+treated+CLLSLL/26642870.html Sun, 14 Jun 2026 03:15:00 -0400 A.20922990 LLY O.00048977 O.03044482 http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html <p>Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.</p><p>Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html Fri, 12 Jun 2026 14:42:02 -0400 ABBV BMY JNJ LLY NVO VRTX http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html <p>Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.</p><p>Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html Fri, 12 Jun 2026 14:42:02 -0400 ABBV BMY JNJ LLY NVO VRTX http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html <p>Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.</p><p>Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html Fri, 12 Jun 2026 14:42:02 -0400 ABBV BMY JNJ LLY NVO VRTX http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html <p>Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.</p><p>Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html Fri, 12 Jun 2026 14:42:02 -0400 ABBV BMY JNJ LLY NVO VRTX http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html <p>Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.</p><p>Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html Fri, 12 Jun 2026 14:42:02 -0400 ABBV BMY JNJ LLY NVO VRTX http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html <p>Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.</p><p>Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while http://www.streetinsider.com/General+News/Leerink+highlights+drug+demand+rebound+after+Memorial+Day/26640164.html Fri, 12 Jun 2026 14:42:02 -0400 ABBV BMY JNJ LLY NVO VRTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ELI+LILLY+%26amp%3B+Co++++++++For%3A+Jun+10++Filed+by%3A+Yuffa+Ilya/26636021.html si-local-file:///var/storage/secattach/20260611/26636021.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ELI+LILLY+%26amp%3B+Co++++++++For%3A+Jun+10++Filed+by%3A+Yuffa+Ilya/26636021.html Thu, 11 Jun 2026 16:23:00 -0400 LLY O.03044482 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ELI+LILLY+%26amp%3B+Co++++++++For%3A+Jun+10++Filed+by%3A+Yuffa+Ilya/26636021.html si-local-file:///var/storage/secattach/20260611/26636021.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ELI+LILLY+%26amp%3B+Co++++++++For%3A+Jun+10++Filed+by%3A+Yuffa+Ilya/26636021.html Thu, 11 Jun 2026 16:23:00 -0400 LLY O.03044482 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ELI+LILLY+%26amp%3B+Co+++++++++++++++++++++Filed+by%3A+Yuffa+Ilya/26628450.html si-local-file:///var/storage/secattach/20260610/26628450.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ELI+LILLY+%26amp%3B+Co+++++++++++++++++++++Filed+by%3A+Yuffa+Ilya/26628450.html Wed, 10 Jun 2026 11:04:00 -0400 LLY O.03044482 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ELI+LILLY+%26amp%3B+Co+++++++++++++++++++++Filed+by%3A+Yuffa+Ilya/26628450.html si-local-file:///var/storage/secattach/20260610/26628450.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ELI+LILLY+%26amp%3B+Co+++++++++++++++++++++Filed+by%3A+Yuffa+Ilya/26628450.html Wed, 10 Jun 2026 11:04:00 -0400 LLY O.03044482 http://www.streetinsider.com/Press+Releases/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html <div class="xn-content"> <p class="prntac"><i>In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it</i></p><p class="prntac"><i>Zepbound</i>^®<i> (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should be used along with a reduced-calorie diet and increased physical activity</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced that basketball legend and cultural icon <person>Shaquille O'Neal</person> is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight http://www.streetinsider.com/Press+Releases/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html Wed, 10 Jun 2026 09:30:00 -0400 LLY O.03044482 http://www.streetinsider.com/Press+Releases/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html <div class="xn-content"> <p class="prntac"><i>In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it</i></p><p class="prntac"><i>Zepbound</i>^®<i> (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should be used along with a reduced-calorie diet and increased physical activity</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced that basketball legend and cultural icon <person>Shaquille O'Neal</person> is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight http://www.streetinsider.com/Press+Releases/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html Wed, 10 Jun 2026 09:30:00 -0400 LLY O.03044482 http://www.streetinsider.com/PRNewswire/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html <div class="xn-content"> <p class="prntac"><i>In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it</i></p><p class="prntac"><i>Zepbound</i>^®<i> (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should be used along with a reduced-calorie diet and increased physical activity</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced that basketball legend and cultural icon <person>Shaquille O'Neal</person> is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight http://www.streetinsider.com/PRNewswire/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html Wed, 10 Jun 2026 09:30:00 -0400 LLY O.03044482 http://www.streetinsider.com/PRNewswire/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html <div class="xn-content"> <p class="prntac"><i>In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it</i></p><p class="prntac"><i>Zepbound</i>^®<i> (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should be used along with a reduced-calorie diet and increased physical activity</i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) today announced that basketball legend and cultural icon <person>Shaquille O'Neal</person> is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight http://www.streetinsider.com/PRNewswire/Zepbound+%28tirzepatide%29+and+Shaquille+O%27Neal+launch+national+campaign+after+NBA+legend+learns+the+obstructive+sleep+apnea+he+has+lived+with+for+years+is+treatable/26627917.html Wed, 10 Jun 2026 09:30:00 -0400 LLY O.03044482